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ABSTRACT

Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of
using black bear PTH and functional fragments for increasing
cAMP in a bone-forming cell; reducing apoptosis in a boneforming cell; decreasing the ratio of expression levels of Bax
protein to Bcl-2 protein in a bone-forming cell; increasing the
expression level of one or more of a bone matrix protein, a
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1
0
0
monkey SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFIALGAP
human SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAP
horse SVSEIQLMHNLGKHLNSVERVEWLRKKLQDVHNFIALGAP
SVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNFVALGAP
dog
cat
SVSEIQFMHNLGKHLSSVERVEWLRRKLQDVHNFVALGAP
bear
SVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNFVALGAP
bovine AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNFVALGAS
SVSEIQLMHNLGKHLSSLERVEWLRKKLQDVHNFVALGAS
pig
rat
AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNFVSLGVQ
mouse AVSEIQLMHNLGKHLASMERMQWLRRKLQDMHNFVSLGVQ
4
5
6
7
8
8
1
0
0
0
0
4
monkey LAPRDAGSQRPRKKEDNILVESHEKSLGEADKADVDVLTKAKSQ
human LAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTKAKSQ
horse IFHRDGGSQRPRKKEDNVLIESHQXSLGEADKADVDVLSKTKSQ
IAHRDGSSQRPLKKEDNVLVESYQKSLGEADKADVDVLTKAKSQ
dog
IAHRDGGSQRPRKKEDNVPAENHQKSLGEADKADVDVLIKAKSQ
cat
bear
TAHRDGGSQRPQKKEDNVLVENHQKSLGEADKADVDVLTKSKPQ
bovine IAYRDGSSQRPRKKEDNVLVESHQKSLGEADKADVDVLIKAKPQ
IVHRDGGSQRPRKKEDNVLVESHQKSLGEADKAAVDVLIKAKPQ
pig
MAAREGSYQRPTKKEENVLVDGNSKSLGEGDKADVDVLVKAKSQ
rat
mouse MAARDGSHQKPTKKEENVLVDGNPKSLGEGDKADVDVLVKSKSQ
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METHODS OF USING BLACK BEAR
PARATHYROID HORMONE

a polypeptide comprising amino acid residues 1-34 of SEQ
ID NO: 2, wherein contacting the bone-forming cell with the
polypeptide decreases the ratio of expression levels of Bax
protein to Bcl-2 protein in the bone-forming cell.
In yet another embodiment, the invention provides a
method of increasing the expression level of a bone matrix
protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell comprising contacting the boneforming cell with an effective amount of a polypeptide comprising amino acid residues 1-34 of SEQ ID NO: 2, wherein
contacting the bone-forming cell with the polypeptide
increases the expression level of the bone matrix protein, the
transcriptional activator, or the transcriptional regulator in the
bone-forming cell.
In still another embodiment, the invention provides a
method of enhancing bone mineral density, increasing bone
mass, decreasing bone loss, or reducing the incidence of bone
fractures in a subject, comprising contacting a bone-forming
cell in the subject with an effective amount of a polypeptide
comprising amino acid residues 1-34 of SEQ ID NO: 2,
wherein contacting the bone-forming cell with the polypeptide enhances bone mineral density, increases bone mass,
decreases bone loss, or reduces the incidence of bone fractures in the subject.
In yet another embodiment, the invention provides a
method of enhancing bone mineral density, increasing bone
mass, decreasing bone loss, or reducing the incidence of bone
fractures, or any combination thereof, in a subject, comprising contacting a bone-forming cell in the subject with an
effective amount of a polypeptide comprising bear parathyroid hormone or a functional fragment thereof, wherein contacting the bone-forming cell with the polypeptide enhances
bone mineral density, increases bone mass, decreases bone
loss, or reduces the incidence of bone fractures in the subject.
In still another embodiment, the invention provides an
isolated polypeptide consisting essentially of amino acid residues 1-34 of SEQ ID NO: 2.
In yet another embodiment, the invention provides an isolated polypeptide consisting essentially of amino acid residues 1-36 of SEQ ID NO: 2.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of U.S. Provisional
Application No. 60/736,145, filed Nov. 10, 2005, which is
incorporated herein by reference in its entirety.
IO

STATEMENT REGARDING
FEDERALLY-SPONSORED RESEARCH
This invention was made with United States government
support awarded by the National Institutes of Health (NIAMS
AR050420 and NIA R21AA 14399-01A2) and the National
Science Foundation (IBN-0343515). The United States government has certain rights in this invention.
BACKGROUND
Bone loss diseases are currently a health threat for approximately 44 million Americans, including 10 million with
osteoporosis and 34 million with low bone mass and at risk
for developing osteoporosis. The number of Americans with
osteoporosis is expected to rise by 2020. Consequently, a
large number ofindividuals are at risk for bone fracture due to
low bone mass. Approximately 40% of white women and
13% of white men over age 50 are at risk for hip, spine, or
forearm fracture within their lifetime. The costs associated
with osteoporosis-related fractures were approximately $18
billion dollars in 2002, and are expected to continue climbing.
In addition to primary (age-related) osteoporosis, disuse
osteoporosis is an important clinical problem, especially for
patients chronically immobilized due to stroke or spinal cord
injury. Fracture rates double compared to healthy controls in
the first year following spinal cord injury and are also elevated
compared to healthy controls after the onset of stroke. Disuse
increases fracture rates primarily because reduced skeletal
loading causes unbalanced bone remodeling which leads to
bone loss.
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SUMMARY
BRIEF DESCRIPTION OF THE DRAWINGS
In one embodiment, the invention provides an isolated
polypeptide comprising at least 10 consecutive amino acid
residues of SEQ ID NO: 2 wherein the polypeptide comprises
at least one of amino acid residues 41 and 52 of SEQ ID NO:
2. The present invention also provides an isolated polynucleotide comprising SEQ ID NO: 1.
In another embodiment, the invention provides a method of
increasing cAMP levels in a bone-forming cell comprising
contacting the bone-forming cell with an effective amount of
a polypeptide comprising amino acid residues 1-34 of SEQ
ID NO: 2, wherein contacting the bone-forming cell with the
polypeptide increases cAMP levels in the bone-forming cell.
In yet another embodiment, the invention provides a
method of reducing apoptosis in a bone-forming cell comprising contacting the bone-forming cell with an effective
amount of a polypeptide comprising amino acid residues 1-34
of SEQ ID NO: 2, wherein contacting the bone-forming cell
with the polypeptide reduces apoptosis in the bone-forming
cell.
In still another embodiment, the invention provides a
method of decreasing the ratio of expression levels of Bax
protein to Bcl-2 protein in a bone-forming cell comprising
contacting the bone-forming cell with an effective amount of
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FIG. 1 shows ultimate stress, a measure of bone strength,
and ash fraction, a measure of bone mineral content, which
both increase with age in black bears.
FIG. 2 shows that serum osteocalcin levels are positively
correlated with serum parathyroid hormone (PTH) levels
(p=0.0007, n=27) in black bears for pooled pre-hibernation,
hibernation, and post-hibernation samples.
FIG. 3 shows normalized serum resorption (ICTP) and
formation (PICP and osteocalcin) marker concentrations during the 3 month disuse period.
FIG. 4 shows that the amount of PGE 2 released by osteoblastic cells was greatest when the cells were treated with
serum collected in the post-hibernation period.
FIG. 5 shows the sequence of the mature black bear PTH
protein (SEQ ID NO: 2) compared to other known PTH
sequences, including monkey (SEQ ID NO: 5), human (SEQ
ID NO: 6), horse (SEQ ID NO: 7), dog (SEQ ID NO: 8), cat
(SEQ ID NO: 9), bovine (SEQ ID NO: 10), pig (SEQ ID NO:
11), rat (SEQ ID NO: 12), and mouse (SEQ ID NO: 13).
FIG. 6 shows that both human and black bear PTH 1-34
upregulate osteocalcin (n=2).
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FIG. 7 shows the effects of human and black bear PTH 1-34
on apoptosis-related gene expression (n=4).

during hibernation, 1t 1s likely that most of the calcium
released from bone by resorption is recycled back into bone
via osteoblastic bone formation. Ionized calcium is found to
increase by about 23% during hibernation, possibly because
of the lag time between resorption and formation. Paradoxically, black bear PTH levels are highest when levels of ionized calcium are highest (Table 1). Taken together, these
findings suggest that bears have evolved biological mechanisms to avoid osteoporosis.
The mechanisms that uncouple bone formation from
resorption during disuse in most animals are unknown, but
likely involve both mechanical and biochemical factors. Lack
of mechanical strain may lead to increased resorption by
initiating osteocyte apoptosis and concomitantly reducing
osteoblastic activity. Hormones such as human PTH can sensitize bone cells to mechanical stimulation and synergistically, with mechanical loading, increase bone formation.
Human PTH given once daily to humans increases bone mass
and decreases fracture incidence. Thus, in black bears, circulating PTH may sensitize bone cells to low levels of mechanical stimulation (possibly due to shivering or repositioning in
the hibernaculum) to help maintain bone formation during
disuse. PTH may also help maintain bone formation in black
bears by stimulating osteoblast differentiation and inhibiting
osteoblast apoptosis.
PTH is the primary regulator of blood calcium levels, and
thus plays a role in maintaining homeostatic serum calcium
levels in black bears during disuse. Serum PTH levels are
positively correlated with the bone formation marker osteocalcin in active and hibernating black bears (FIG. 2), and both
osteocalcin and PTH increase during hibernation. In addition,
black bear PTH concentration is highest when ionized calcium concentration is highest. Since bone resorption
increases during hibernation but total serum calcium (tCa)
remains unchanged, increased levels of PTH likely cause
increased renal reabsorption of calcium, facilitating the recycling of mineral back into the bone with a balanced increase
in bone formation. This leads to the observed preservation of
trabecular and cortical bone properties like bone mineral
density ("BMD") and cortical porosity. Bone resorption
increases during hibernation, but blood calcium concentration remains constant despite the fact that bears do not excrete
waste during hibernation. The calcium liberated by bone
resorption during hibernation may be recycled and put back
into bone by maintaining balanced coupling of bone formation with bone resorption. This supports the idea that PTH has
anabolic effects in hibernating black bears and provides an
explanation for the bears' distinctive ability to maintain balanced bone remodeling during hibernation. The anabolic
effects of PTH may be enhanced in black bears when physical
activity is resumed following arousal from hibernation.
Mechanical loading and human PTH have previously been
shown to act synergistically to increase bone formation in
vivo in rats and biochemical signaling in vitro. During remobilization in the spring, bone formation in the black bear, as
indicated by serum osteocalcin, remains higher than prehibernation levels.
The sequence for the polynucleotide which encodes black
bear (Ursus americanus) parathyroid hormone (PTH) (SEQ
ID NO: 1) was discovered as well as the polypeptide sequence
for the mature 84 amino acid PTH protein (SEQ ID NO: 2). In
addition, the cDNA (SEQ ID NO: 3) which encodes the full
length PTH protein (SEQ ID NO: 4), including a 25 amino
acid signal peptide (amino acid residues 1-25 of SEQ ID NO:
4) and a 6 amino acid propeptide (amino acid residues 26-31
of SEQ ID NO: 4) has been sequenced. The mature black bear
PTH protein differs from other known PTH proteins (FIG. 5).
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In humans and most other mammals, factors such as aging
and extended periods of disuse can lead to osteoporosis and
an increased risk of fracture. Disuse due to spinal cord lesion
significantly decreases bone mineral density, particularly in
the tibia and femur, and significantly reduces the cross-sectional moment ofinertia of the femoral diaphysis. Thus, bone
bending strength is reduced by spinal cord injury and fracture
risk is increased. Disuse due to stroke also increases fracture
risk. In addition, mechanical unloading of bone can cause
rapid bone loss due to immediate increases in bone resorption
in addition to sustained decreases in bone formation. Disuseinduced changes in bone remodeling increase intracortical
porosity, and reduce the cross-sectional and mechanical properties of long bone diaphyses. Unloading also considerably
reduces trabecular bone mass and microarchitecture.
The deleterious effects of disuse on bone may continue into
the remobilization period. Some bone may be recovered during remobilization, but recovery is slow and often incomplete. For example, the rate of bone loss during bedrest is
more than three times greater than the rate of bone gain during
remobilization, and the recovery of bone lost in spaceflight
can be incomplete even after 5 years. When disuse-induced
changes in bone can be completely reversed by resumed
activity, the remobilization period is often 2 to 3 times longer
than the immobilization period. Bone formation decreases
and/or bone resorption increases in many situations that
reduce mechanical loads on bone. However, both resorption
and formation increase during canine forelimb immobilization, yet there is significant bone loss in that case. Likewise,
thigh bone turnover occurs in patients with spinal cord injury,
which leads to bone loss and increased fracture incidence.
In contrast to this, black bears do not suffer significant bone
loss due either to aging (FIG. 1) or, more importantly, to the
extended periods of disuse that occur during hibernation.
Hibernating black bears have immobilization and active periods that can be approximately equal in length in northern
regions. Data on serum markers of bone metabolism (see
below) suggest that both resorption and formation increase
during disuse in bears, with a normal lag time (i.e., reversal
period) between resorption and formation, and that the
increase in formation remains coupled and balanced with the
increase in resorption. Histological data from black bear iliac
crest biopsies also show increased resorption and formation
during inactivity. However, bears are unique in that trabecular
bone volume, bone mineral density, and bone mineral content
do not decrease during hibernation. Moreover, cortical bone
strength and ash fraction increase with age, and porosity does
not change with age in black bears, despite annual periods of
disuse. Cortical bone porosity is significantly lower in hibernating grizzly bears than in active grizzly bears, and femoral
cross-sectional geometry and strength are unaffected by
hibernation.
Bears have evolved many unique biological mechanisms to
survive long periods of immobilization without food. These
mechanisms appear to include the recycling of calcium and
other products of bone catabolism, since bears increase bone
turnover but do not excrete waste during hibernation. In
humans, bedrest-induced disuse osteoporosis is caused primarily by increased resorption without a corresponding
increase in formation. This results in hypercalcemia and a
negative calcium balance brought about by increased urinary
and fecal calcium. Since bears do not urinate or defecate
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Compared to human PTH, black bear PTH has 11 different
amino acid residues out of a total of the 84 amino acid residues of the full-length, mature PTH polypeptide. Also
described herein are various methods of use for black bear
PTH and functional fragments thereof. It is specifically envisioned that polypeptide subfragments comprising at least 10
consecutive amino acid residues of SEQ ID NO: 2 and including at least one of amino acid residues 41 or 52 can be used to
develop antibodies specific for black bear PTH. These antibodies can be used to quantify black bear PTH, e.g. in an
ELISA assay.
PTH receptors on the surface of bone-forming cells are
coupled to cyclic adenosine monophosphate (cAMP)-dependent second-messenger signaling pathways inside the cells.
These signaling pathways, in turn, lead to increased expression of genes involved in bone formation such as those encoding type I collagen, osteonectin, and osteopontin. Since the
cAMP/protein kinase A pathway is responsible for the majority of PTH-induced increases in histological and serum indices of bone formation, it follows that an increased cAMP
response can lead to greater bone formation. A relatively
small number of amino acid substitutions in the sequence of
a given PTH protein can stimulate greater cyclic adenosine
monophosphate (cAMP) production compared to the native
form. For example, ovariectomized rats demonstrated a 25%
greater bone formation response to daily 25 µg injections of
bovine PTH 1-34 than to rat PTH 1-34, where rat PTH 1-34
has 5 amino acid sequence differences compared to bovine
PTH 1-34. Injection of bovine PTH 1-34 results in a 37%
greater increase in bone volume fraction during treatment.
Thus, it is likely that the amino acid substitutions in black
bear PTH cause it to induce greater cAMP production in
bone-forming cells than human PTH. PTH, in general, elicits
a greater bone formation response by mechanisms such as
decreasing osteoblast apoptosis, increasing osteoblast differentiation via Runx2, downregulating SOST-based negative
feedback in osteocytes, and increasing production of mRNA
for bone matrix proteins, all via cAMP-mediated pathways.
Although it is not necessary to understand the mechanism of
an invention, it is believed that black bear PTH is likely more
osteogenic than other forms of PTH, which explains why
black bears are uniquely able to maintain balanced bone
remodeling during disuse. In another embodiment of the
present invention, contacting a bone-forming cell with black
bear PTH or a functional fragment thereof increases cAMP
levels in the bone-forming cell. In another embodiment of the
present invention, the bone-forming cell is contacted with a
polypeptide comprising amino acid residues 1-34 or 1-36 of
SEQ ID NO: 2. In another embodiment of the present invention, the bone-forming cell is contacted with a polypeptide
comprising SEQ ID NO: 2. In another embodiment, the boneforming cell is contacted with a polypeptide comprising
amino acid residues 11-84 or 7-84 of SEQ ID NO: 2.
As used herein, "contacting a cell" with a PTH polypeptide
includes adding the polypeptide to the culture solution, in the
case of in vitro experiments, or administering the polypeptide
to a subject using appropriate administration procedures for
polypeptide therapeutic agents. "Contacting a cell" also
includes introducing into a subject an exogenous polynucleotide that encodes the desired polypeptide in an expression
system so as to synthesize and release the polypeptide in the
subject. As used herein, "bone-forming cells" includes, but is
not limited to, osteoblasts, osteocytes, bone lining cells,
chondroblasts, and chondrocytes. Suitably, the bone-forming
cell may be in a subject.
Bone-forming cells regularly tum over, with most of the
cells' death being due to programmed cell death, or apoptosis.

Given this regular rate of turnover, any mechanism that
decreases apoptosis of bone-forming cells will lead to an
increased number of bone-forming cells which presumably
will promote bone growth. Thus, in another embodiment of
the present invention, contacting a bone-forming cell with
black bear PTH or a functional fragment thereof reduces
apoptosis in the bone-forming cell. In another embodiment of
the present invention, the bone-forming cell is contacted with
a polypeptide comprising amino acid residues 1-34 or 1-36 of
SEQ ID NO: 2. In another embodiment of the present invention, the bone-forming cell is contacted with a polypeptide
comprising SEQ ID NO: 2.
Moreover, it is possible that several of the larger C-terminal
fragments of endogenous black bear PTH play a role in seasonal bone remodeling processes via binding to CPTHRs
(C-terminal PTH receptors). Specifically, C-terminal fragments of bear PTH may antagonize the calcemic effects of
PTH 1-84 and 1-34 by preventing osteoclastogenesis and
possibly by affecting mature osteoclast activity that would
normally occur in response to resorptive stimuli such as disuse (Divieti, P. et al., 2002, Endocrinology 143(1): 171-6).
This may help bears to maintain homeostatic calcium levels
throughout hibernation. Thus, in another embodiment of the
present invention, osteocytes and osteoblasts may be contacted with a polypeptide comprising amino acid residues
11-84 or 7-84 of SEQ ID NO: 2.
The protein Bax promotes apoptosis while the Bcl-2 protein protects cells from apoptosis, and a decrease in the
expression ratio of Bax to Bcl-2 is indicative of a decrease in
apoptosis in the particular cell population. Thus, in another
embodiment of the present invention, contacting a boneforming cell with black bear PTH or a functional fragment
thereof decreases the ratio of expression levels of Bax protein
relative to expression levels of Bcl-2 protein in the boneforming cell. In another embodiment of the present invention,
the bone-forming cell is contacted with a polypeptide comprising amino acid residues 1-34 or 1-36 of SEQ ID NO: 2. In
another embodiment of the present invention, the bone-forming cell is contacted with a polypeptide comprising SEQ ID
NO: 2. In another embodiment of the present invention, the
bone-forming cell is contacted with a polypeptide comprising
amino acid residues 11-84 or 7-84 of SEQ ID NO: 2.
Example 11 shows that black bear PTH 1-34 decreases the
expression ratio of Bax/Bcl-2 in cultured cells whereas
human PTH 1-34 increases the expression ratio ofBax/Bcl-2
(FIG. 7). Thus, black bear PTH 1-34 appears to be more
effective at preventing apoptosis than human PTH 1-34.
Without being bound by theory, this difference may be the
result of the two amino acid differences between human and
black bear PTH 1-34. These data suggest that bear PTH is
more anabolic than human PTH, since decreased osteoblast
apoptosis may contribute to the bone formation response
induced by PTH treatment.
Contacting a bone-forming cell with black bear PTH or a
functional fragment thereof also increases the expression
level of bone matrix protein, a transcriptional activator, or a
transcriptional regulator in the bone-forming cell. In another
embodiment of the present invention, the transcriptional activator is Runx2. In another embodiment of the present invention, the transcriptional regulator is c-fos. Bone matrix proteins may suitably include osteocalcin, osteopontin, and type
I collagen. In another embodiment of the present invention,
the bone-forming cell is contacted with a polypeptide comprising amino acid residues 1-34 or 1-36 of SEQ ID NO: 2. In
another embodiment of the present invention, the bone-forming cell is contacted with a polypeptide comprising SEQ ID
NO: 2. In another embodiment of the present invention, the
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bone-forming cell is contacted with a polypeptide comprising
amino acid residues 11-84 or 7-84 of SEQ ID NO: 2.
Exogenous human PTH is used to treat post-menopausal
and age-related osteoporosis in humans, but it is not an ideal
therapeutic. Only recombinant human PTH 1-34 (LY333334,
Eli Lilly, Indianapolis Ind.) is currently approved for clinical
use, and only one form of recombinant human PTH 1-84 is
under consideration for approval by the U.S. Food and Drug
Administration (ALXl-11, NPS Pharmaceuticals, Parsippany, N.J.). Though LY333334 and ALXl-11 can stimulate
approximately the same magnitude ofbone formation in vivo,
their biological actions are not identical. For example, PTH
1-34 down-regulates production of procollagen-1 mRNA,
whereas PTH 1-84 does not (Nasu et al., 1998, Endocr J, 45,
229-34). In addition, it has also been determined that the
C-terminal portion of human PTH, when cleaved from the
mature hormone, has important biological functions such as
inhibition of bone resorption.
Long-term usage of either LY333334 or ALXl-11 generates osteosarcoma in rats, but preliminary results indicate that
human PTH 1-84 has a lower rate of carcinogenicity than
human PTH 1-34, possibly because C-terminal fragments of
exogenous human PTH 1-84 (arising from peripheral proteolytic processing) can bind to C-terminal PTH receptors
(CPTHRs) and increase osteocyte apoptosis. Thus, though
equally anabolic, human PTH 1-84 may be a superior
osteoporosis therapy compared to human PTH 1-34. However, human PTH 1-84 cannot completely restore lost bone; it
has been suggested that men and women can lose between
20-30% of cortical and cancellous bone due to age-related
osteoporosis, but only 8% is recovered using ALXl-11 during its suggested treatment regimen. Therefore, there exists a
clinical need for osteoporosis treatments with greater osteogenic capabilities.
In an additional embodiment of the present invention, contacting a bone-forming cell in a subject with black bear PTH
or a functional fragment thereof increases bone mineral density, increases bone mass, decreases bone loss or reduces the
incidence of bone fracture in the subject. In another embodiment of the present invention, the bone-forming cell is contacted with a polypeptide comprising amino acid residues
1-34 or 1-36 of SEQ ID NO: 2. In another embodiment of the
present invention, the bone-forming cell is contacted with a
polypeptide comprising SEQ ID NO: 2. In another embodiment of the present invention, the bone-forming cell is contacted with a polypeptide comprising amino acid residues
11-84 or 7-84 of SEQ ID NO: 2.
Suitably, contacting a bone-forming cell in a subject with
black bear PTH or a functional fragment thereof increases
bone mineral density, increases bone mass, decreases bone
loss or reduces the incidence of bone fracture by at least about
5% or at least about 10%. The increase in bone mineral
density, increase in bone mass, decrease in bone loss or reduction in the incidence of bone fracture may be at least about
15%, at least about 30%, at least about 50%, at least about
75% or at least about 90%. The increase in bone mineral
density, increase in bone mass, decrease in bone loss or reduction in the incidence of bone fracture is determined by measuring the desired characteristic on the same patient before
and after treatment by a technique known to one of ordinary
skill in the art. For example, bone mineral density can be
determined by methods involving taking dual energy x-rays
(DEXA) or CT scans ofbones in the spinal colurmi, wrist, arm
or leg.
The subject may suitably be a mammal, including without
limitation human, horse, dog, cat, mouse, bear, bovine, pig, or
deer. The subject may have osteoporosis or may be at risk to

develop osteoporosis. Risk factors for developing osteoporosis include: personal history of fracture after age 50; current
low bone mass; history of fracture in a first-degree relative;
being female; being thin and/or having a small frame;
advanced age; a family history of osteoporosis; estrogen deficiency as a result of menopause, especially early or surgically
induced; abnormal absence of menstrual periods (amenorrhea); anorexia nervosa; low lifetime calcium intake; vitamin
D deficiency; use of certain medications (corticosteroids,
chemotherapy, anticonvulsants and others); presence of certain chronic medical conditions, such as those that decrease
calcium absorption in the gut such as Crohn's disease; low
testosterone levels in men; an inactive lifestyle; current cigarette smoking; excessive use of alcohol; and being Caucasian
or Asian; although African Americans and Hispanic Americans are at significant risk as well. Moreover, women can lose
up to 20 percent of their bone mass in the five to seven years
following menopause, making them more susceptible to
osteoporosis.
Black bear PTH or functional fragments thereof are also
useful as a preventative (rather than a restorative), or prophylactic, measure to combat disuse osteoporosis or to prevent
osteoporosis in a subject at risk for developing osteoporosis.
Since bears appear to be the only animals that maintain balanced bone remodeling during disuse, black bear PTH or
functional fragments thereof are also useful to prevent bone
loss during reduced skeletal unloading that occurs, for
example, in astronauts during spaceflight and in spinal cord
injury patients after injury.
Black bear PTH or functional fragments thereof may be
administered in combination with calcium and/or vitamin D.
The calcium and/or vitamin D may be administered concurrently with black bear PTH or functional fragment thereof or
may be administered before or after black bear PTH or functional fragments thereof. Suitably, "Vitamin D" refers to the
entire Vitamin D class of compounds.
Administration of black bear PTH or functional fragments
thereof or compositions comprising black bear PTH or functional fragments thereof can be accomplished by any suitable
technique. Black bear PTH or functional fragment thereof
may be administered by any suitable route including, for
example, oral, nasal, rectal, and parenteral routes of administration. As used herein, the term parenteral includes but is
not limited to subcutaneous, intradermal, intravenous, intramuscular, intraperitoneal, and intrathecal administration,
such as by injection. As is discussed above, administration of
a polypeptide includes administration of an exogenous polynucleotide operably connected to a promoter such that the
polynucleotide expresses the polypeptide in the subject.
Administration of the polypeptide also includes administration of a viral vector comprising a polynucleotide encoding
the polypeptide. Suitably, the viral vector is an adenoviral
vector.
Black bear PTH or functional fragments thereof, or compositions comprising black bear PTH or functional fragments
thereof, can be administered continuously or at discrete time
intervals as can be readily determined by a person skilled in
the art. An ordinarily skilled clinician can determine a suitable amount of black bear PTH or a functional fragment
thereof to be administered to a subject.
The specific effective dose for any particular subject will
depend upon a variety of factors, including the disorder being
treated and the severity of the disorder; activity of the specific
compound employed; the specific composition employed; the
age, body weight, general health, sex and diet of the subject;
route of administration; the rate of excretion or inactivation of
black bear PTH or functional fragments thereof employed;
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the duration of the treatment; other pharmaceuticals used in
combination or coincidental with black bear PTH or functional fragments thereof and like factors well known in the
medical arts. For example, it is well within the level of ordinary skill in the art to start doses at levels lower than those
required to achieve the desired effect and to gradually
increase the dosage until the desired effect is achieved.
Suitably, the dosage of black bear PTH or functional fragments thereof in one embodiment is in a range of 0.10 µg/kg
per day to 40 µg/kg per day. In another embodiment, the
dosage is in a range of 5 µg/kg per day to 20 µg/kg per day. In
still another embodiment, the dosage is 10 µg/kg per day. In
another embodiment, the dosage is in a range of 10 µg/day to
400 µg/day per subject. In yet another embodiment, the dosage is in a range of20 µg/day to 40 µg/day per subject. In still
another embodiment, the dosage is 30 µg/day per subject. In
one embodiment the subject is a human. Suitably, the daily
dosages in one embodiment are given for one week, in
another embodiment for one month, in yet another embodiment for three months, in yet another embodiment for six
months, in still another embodiment for one year, in yet
another embodiment for one and a half years, in still another
embodiment for two years, and in yet another embodiment for
three years.
If desired, the effective daily dose may be divided into
multiple doses for purposes of administration. Consequently,
single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. If desired, a
suitable delivery device is loaded with the effective daily dose
for more than one day, for example, for seven days, fourteen
days, twenty-one days, twenty-eight days or the like, and the
delivery device is used to repeatedly administer the desired
daily single dose or daily multiple doses for the desired total
numberof days. As noted, those ofordinary skill in the art will
readily optimize effective doses and co-administration regimens as determined by good medical practice and the clinical
condition of the individual subject.
Compositions containing black bear PTH or functional
fragments thereof useful in the methods of the present invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations
are described in detail in a number of sources which are well
known and readily available to those skilled in the art. For
example, Remington's Pharmaceutical Science, by E. W.
Martin, describes formulations which can be used in the
disclosed methods. In general, the compositions will be formulated such that an effective amount of the polypeptide is
combined with a suitable carrier in order to facilitate effective
administration of the composition.
The compositions used in the present methods can also be
in a variety of forms. These include, for example, solid, semisolid, and liquid dosage forms, such as tablets, pills, powders,
liquid solutions or suspension, suppositories, injectable and
infusible solutions, and sprays. The form will depend on the
intended mode of administration and therapeutic application.
The compositions also suitably include conventional pharmaceutically acceptable excipients which are known to those
skilled in the art. Examples of excipients include water for
injection, ethanol, dimethyl sulfoxide, glycerol, alumina,
starch, glacial acetic acid, sodium acetate, mannitol, metacresol, hydrochloric acid and/or sodium hydroxide to adjust
the pH of a composition to a suitable value, and equivalent or
otherwise suitable carriers and diluents. To provide for the
administration of such dosages for the desired application,
pharmaceutical compositions will comprise between about
0.1% and 99%, and suitably between about 1 and 15% by
weight of the total of one or more of the polypeptides of the
present invention based on the weight of the total composition
including the carrier or diluent.

As used herein, an "isolated" nucleic acid molecule, polynucleotide, polypeptide, or the like, as the case may be, refers
to a component that is at least partially purified from contaminants (e.g., other species of polynucleotides, polypeptides, or
the like) that is found other than in its natural state. An isolated
nucleic acid, polynucleotide, or polypeptide may contain less
than about 50%, suitably less than about 75%, and most
suitably less than about 90%, of the cellular components with
which it was originally associated. A polynucleotide amplifled using PCR so that it is sufficiently and easily distinguishable (on a gel, for example) from the rest of the cellular
components is considered "isolated". The nucleic acid molecules, polynucleotides, and polypeptides of the invention
may be "substantially pure," i.e., having the highest degree of
purity that can be achieved using purification techniques
known in the art.
As used herein, a "functional fragment" refers to any
region or portion of a polypeptide or polynucleotide which is
a region or portion of a larger polypeptide or polynucleotide,
the region or portion having an activity or function attributable to the larger polypeptide orpolynucleotide. For example,
a functional fragment of human PTH is the 1-34 region of
humanPTH.
As used in this specification and the appended claims, the
singular forms "a," "an," and "the" include plural referents
unless the content clearly dictates otherwise. It should also be
noted that the term "or" is generally employed in its sense
including "and/or" unless the content clearly dictates otherwise. All publications, patents and patent applications are
herein expressly incorporated by reference in their entirety
for all purposes to the same extent as if each individual
publication or patent application was specifically and individually incorporated by reference. In case of conflict
between the present disclosure and the incorporated patents,
publications and references, the present disclosure should
control.
It also is specifically understood that any numerical range
recited herein includes all values from the lower value to the
upper value, i.e., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application. For example, if a concentration range is stated as 1%
to 50%, it is intended that values such as 2% to 40%, 10% to
30%, or 1% to 3%, etc., are expressly enumerated in this
specification. If a concentration range is "at least 5%," it is
intended that all percentage values up to and including 100%
are also expressly enumerated. These are only examples of
what is specifically intended.
The following Examples are provided to assist in a further
understanding of the invention. The particular materials,
methods and conditions employed are intended to be illustrative of the invention and are not limiting upon the scope of the
invention.
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Sequencing of Black Bear PTH 1-84
Genomic DNA Extraction
Blood was collected from a captive female black bear and
stored at 4° C. Genomic DNA was extracted from the whole
blood samples within 2 weeks, using the Genomic Prep Blood
DNA Isolation Kit (Amersham Biosciences, Piscataway,
N.J.) according to the manufacturer's instructions.
PCR Cloning and Sequencing
Black bear genomic DNA was used for PCR amplification
of PTH, using consensus primers designed based on alignment of eight full-length mammalian PTH sequences available in GenBank including bovine (Bos faun.ts, AAA30749),
cat (Pelis catus, Q9GL67), dog (Canisfamiliaris, P52212),
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human (Homo sapiens, NP_000306), macaque (Macacafascicularis, Q9XT35), mouse (Mus musculus, NP_065648),
pig (Sus scrofa, NP_999566), and rat (Rattus norvegicus,
NP_0587 40). PCR amplification was performed using 10-15
ng genomic DNA, 100 µM dNTPs, 0.2 µMeach primer, and
1 unit REDTaq (Sigma, St. Louis, Mo.) in 20 µL reaction
volume. PCR products were gel-purified using the Ultra Clean
GelSpin Kit (MoBio Carlsbad, Calif.) and cloned into the
pCRII vector using the TA cloning kit (Invitrogen, Carlsbad,
Calif.). DNA sequencing was performed using the DTCS
Quick Start kit and the CEQ8000 Genetic Analysis System
(Beckman Coulter, Fullerton, Calif.), following the manufacturer's instructions.
Sequence Analysis
Nucleotide sequences were searched against the GenBank
protein database using BlastX (Altschul et al., 1997; Nucleic
Acids Res., 25, 3389-402) to confirm their putative identity as
PTH. Multiple sequence alignment was performed by ClustalW version 1.82 (Chenna et al., 2003; Nucleic Acids Res.,
31, 3497-500). Phylogenetic analysis was carried out using
the neighbor-joining (NJ) method implemented in the
Molecular Evolutionary Genetics Analysis (MEGA) package
version 3.0 (Kumar et al., 2004; BriefBioinform., 5, 150-63),
with the pairwise deletion option for handling alignment
gaps, and with the Poisson correction model for distance
computation.
PTH Cloning and Sequence Analysis
Various primer combinations were used for PCR-based
cloning of PTH from black bear genomic DNA. Based on the
sequencing results of preliminary clones, a gene-specific
sense primer corresponding to the start codon was designed
and used along with a degenerate antisense primer containing
the stop codon to amplify the entire coding region of PTH. A
second antisense primer covering the stop codon was
designed to generate a clone for sequence confirmation.
Sequence assembly revealed a precursor PTH protein of
115 amino acids, including a 25 amino acid signal peptide and
a 6 amino acid propeptide. The deduced mature protein is 84
amino acids, with a calculated molecular weight of 9,471
Daltons and a pl of 8.1. Black bear PTH shares 84-95%
sequence similarity with other mammalian PTHs, and is most
similar to dog PTH (91 % identity, 95% similarity) (FIG. 5).
Interestingly, two amino acid residues, 41 and 52 of the
mature hormone, are unique to black bear PTH.

samples were collected from each bear every 10 days from the
first of October through the end of May. Hibernation began in
early January and ended in early April. Thus, the collection
dates encompassed an active pre-hibernation period, a disuse
hibernation period, and an active post-hibernation remobilization period.
Black Bear Osteocalcin Purification and RIA Procedures
Black bear cortical bone was broken into small fragments,
defatted with a mixture of 3 parts hexane and 2 parts isopropanol, and lyophilized. The dried bone was ground to a fine
powder under liquid nitrogen, and the osteocalcin was solubilized as described by Hauschka et al. (1989, Physiol. Rev.,
69, 990-1047). Osteocalcin was purified from the resulting
EDTA extract by a modification of the method of Colombo et
al. (1993, J. Bone Miner. Res., 8, 733-43). Briefly, the crude
EDTA solution was diluted 2-fold and passed over a bulk
column containing 10 g Sepralyte C18 particles (Analytichem International, Harbor City, Calif.) previously activated
with methanol and equilibrated with 0.1 % trifluoroacetic acid
in water (0.1 % TFA).An extensive wash with 0.1% TFA was
followed by 30% methanol/0.1% TFA until UV absorbance
dropped to baseline. Osteocalcin was eluted with 80% methanol/0.1 % TFA. Methanol was evaporated under a stream of
air and the remaining solution lyophilized. The resulting
dried protein was suspended in 0.05 M Tris buffer, pH 8.0 and
applied to a 5 ml Biorad Econo-Q colunm previously equilibrated with the same buffer. The colunm was developed with
a gradient from 0.1 to 0.6 M NaCl in 0.5 M Tris, pH 8.0.
Osteocalcin eluted in a symmetric peak, the last to elute from
the colunm. Identity of this peak as osteocalcin was qualitatively verified by reacting fraction aliquots with diazobenzene sulfonic acid yielding a pink color in those fractions
containing osteocalcin, with intensity corresponding to peak
height. Both the Cl 8 and the Econo-Q column were new and
never exposed to protein from other species. Previous experience with other species suggests the final osteocalcin peak is
greater than 99% pure. Concentration of black bear osteocalcin in the final elute was determined with BCA reagents from
Pierce Chemical (Rockford, Ill.).
Biochemical Assays
The serum was assayed for PTH, 25-OH D, leptin, IGF-I,
and osteocalcin (a bone formation marker) using RIA and
ELISA.
Highly purified black bear osteocalcin and black bear
serum were assayed by radioimmunoassay. The antibody was
guinea-pig anti-rat osteocalcin and tracer was 125 1-labeled rat
osteocalcin. Dose dilutions of both rat osteocalcin standard
(Biomedical Technologies, Inc, Stoughton, Mass.) and purified black bear osteocalcin were included in the assay. Aliquots of 10 µl black bear serum per assay tube were assayed
in duplicate, and all samples were assayed at the same time.
Duplicates varied by less than 5%.
To observe changes in bone formation and resorption
markers during disuse, the mean values of osteocalcin for the
5 black bears were calculated for each time point during the
hibernation period. These values were normalized by the
maximum osteocalcin value during the hibernation period.
Similar calculations were done for measurements of PICP
(bone formation marker) and I CTP (bone resorption marker).
The normalized values of the resorption and formation markers were plotted on the same graph to assess the temporal and
relative magnitude changes in bone resorption and formation
during disuse.
Using serum samples from hibernating bears obtained as
described above, ionized calcium concentration was measured with an ion-selective electrode (Bayer Rapidlab 865,
Leverkusen, Germany).

5

10

15

20

25

30

35

40

45

Example 2
Levels of Bone Resorption and Formation Markers
During Hibernation
50

Serum Samples
Blood samples were collected from five black bears (Ursus
americanus) held in a captive bear research facility. The Virginia Polytechnic Institute and State University Animal Care
Committee approved all bear handling protocols (#98-069F&WS). The bears were anesthetized with a 2:1 mixture of
ketamine (100 mg/ml):xylazine (100 mg/ml); the dosage was
1 cc of the mixture per 45.5 kg of body weight. Body temperatures were 4' to 6° C. cooler during winter collection,
confirming that the bears were in a state of hibernation. No
urine or scat was present in the hibernation dens. Stressful
behavior was not observed during any of the handling procedures. Blood samples were drawn from the femoral vein
while the bears were anesthetized, and the samples were
transported to the laboratory in an ice-packed cooler. Immediately on return to the laboratory, the blood was centrifuged
to isolate the serum, which was frozen at -20° F. Blood
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Using serum samples obtained as described above, PTH
was assayed with an ELISA kit from Immutopics International (San Clemente, Calif.); the intra-assay coefficient of
variation was 4.7%. 25-OH D was assayed with an ELISA kit
fromALPCO Diagnostics (Windham, N.H.); the intra-assay
coefficient of variation was 5%. Leptin was measured by RIA
(Linea, St. Charles, Mo.); the intra-assay coefficient of variation was 3.4%. IGF-I was measured by acid ethanol extraction RIA (Nichols Institute Diagnostics, San Juan Capistrano,
Calif.); the intra-assay coefficient of variation was 4.3%.
Serum osteocalcin was measured by RIA as described above.
For all the serum metabolites, the mean values (for all bears
and all time points within a given season) were calculated for
each season (pre-hibernation, hibernation, and post hibernation) and compared by ANOVA. ANOVAs were followed up
with Fisher's PLSD tests for multiple mean comparisons.
Natural log transformations were used to correct non-constancy of variance for osteocalcin, PTH, 25-OH D, and IGF-I
to validate the ANOVAs. Linear regressions were used to
assess the correlations between osteocalcin and the hormones. The volume of some serum samples was insufficient
to run all assays; sample sizes for each assay are indicated
with the results.
Results
The bone resorption marker (ICTP) began to increase
immediately after the onset of hibernation (FIG. 3). Each data
point is the mean value from 5 bears. After 10-20 days, the
bone formation markers (osteocalcin and PICP) also
increased and appeared to remain coupled to the increased
resorption for the duration of hibernation. This is consistent
with the 1-2 week histological "reversal" period between
resorption and formation. These remodeling markers showed
trends of increased resorption and formation throughout the
hibernation period, and formation appeared to remain
coupled and balanced with resorption. Mean osteocalcin levels were higher (p<0.0001) during and after hibernation compared to pre-hibernation (Table 1).
Hibernation ionized calcium levels were significantly
(p=0.0062) higher than the pre-hibernation levels (Table 1).
During remobilization following arousal from hibernation,
ionized calcium levels did not significantly (p=0.37) increase
relative to hibernation levels, but they remained higher
(p=0.015) than pre-hibernation levels.
Osteocalcin was positively correlated with PTH (FIG. 2),
but not with 25-OH D, leptin, orIGF-I. PTH was significantly
higher in the post-hibernation season than in the pre-hibernation (p=0.006) and hibernation (p=0.014) seasons. The
increase in PTH during hibernation relative to pre-hibernation was not significant (p=0.35). 25-OH vitamin D did not
show seasonal variations (p=0.64).
Serum leptin did not change during hibernation relative to
pre-hibernation, but was significantly (p<0.004) lower during
post-hibernation remobilization (Table 1). IGF-1 significantly (p<0.0001) decreased during hibernation relative to
pre-hibernation and reached its highest value during remobilization (Table 1).

Example 3
PGE 2 Release by MC-3T3 Osteoblasts is Affected by
Seasonal Variations in Bear Serum
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To assess the effects of seasonal variations in bear serum on
osteoblast metabolism, MC-3T3 cells were treated with bear
serum and prostaglandin E 2 (PGE 2 ) release was quantified.
MC-3T3 cells were grown in alpha minimum essential media
(Invitrogen, Carlsbad, Calif.) supplemented with 10% fetal
bovine serum (Hyclone, Logan, Utah) and 1% penicillinstreptomycin solution at 37° C. in 5% CO 2 for 24 hours. The
media was aspirated and replaced with 10 ml of fresh media
containing 10% bear serum collected prior to hibernation,
during hibernation, or after hibernation. The cells were
allowed to grow for an additional 24 hours, and then the
media was collected and frozen at -20° C. for PGE 2 analysis.
The cells were removed from the culture dishes using 0.25%
trypsin in EDTA, pelleted by centrifugation, and quantified
with a trypan blue and hemocytometer.
The PGE 2 levels were determined using the Biotrak™
PGE 2 competitive enzyme immunoassay (Amersham Biosciences, Piscataway, N.J.). The assay was performed in
duplicate using 50 µl samples from all experimental media
samples. The reaction was halted prior to endpoint determination using IM sulfuric acid and read at 450 nm using a
microplate reader (VERSAmax, Molecular Devices Corporation, Sunnyvale, Calif.). The duplicate optical density values were corrected for nonspecific binding and were averaged, and compared to a standard curve to determine the
amount of PGE 2 in each well. These values were corrected for
total media volume and normalized by the number of cells in
the sample. ANOVA was used to compare the normalized
PGE 2 between the three serum groups.
The amount of PGE 2 , released by osteoblastic cells treated
with bear serum in vitro, was higher for treatment with posthibernation serum compared to pre-hibernation serum
(p=0.058) and hibernation serum (p=0.014) (FIG. 4). The
PGE 2 release for cells treated with the hibernation serum was
not significantly (p=0.48) different compared to the pre-hibernation serum. The seasonal changes in PGE 2 release
showed trends similar to the seasonal changes in serum IGF-I.
P-values are for comparisons with the post-hibernation value.
Pre-hibernation and hibernation values were not different
from each other (p=0.48).
Example 4
Culture in Bear Serum Decreases the Ratio of Gene
Expression of Bax to Bcl-2 During Hibernation

50

Blood serum samples were removed from 4 female black
bears between 2004-2005 as described above. Sample dates

TABLE 1
Mean Serum Metabolite Concentrations
Pre-hibernation
Osteocalcin (ng/ml)
Ionized calcium (mmol/L)
PTH (pg/ml)
25-OH D (nmol/ml)
Leptin (ng/ml)
IGF-1 (ng/ml)

16.9a
0.709a
14.6a
16.6
4.oa
3g7a

(7.4)
(.150)
(4.5)
(16.3)
(0.7)
(88)

Hibernation
[15] 70.4b
0.871b
[12]
[6] 25.3a
[9] 11.2
3.sa
[15]
[15] 209b

(43.1)
(.093)
(27.3)
(6.2)
(0.7)
(52)

Post-hibernation
[22] 49.3b
0.960b
[10]
[14] 41.4b
[9] 16.0
3.lb
[22]
[22] 594c

(26.8)
(.014)
(20.2)
(13.4)
(0.7)
(207)

[19]
[2]
[9]
[9]
[19]
[19]

Mean values are given in bold, standard deviations in parentheses, and sample sizes in brackets. For a given metabolite, values with the same superscript
are not significantly (p < 0.05) different. 25-0H D did not show significant seasonal differences.
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encompassed a pre-hibernation active period, a hibernation
disuse period, and a post-hibernation remobilization period.
MC-3T3 osteoblastic cells were cultured for 24 hours in
media containing 10% bear serum, after which total RNA was
isolated using a BioRadAquaPure RNA Isolation Kit (#7326370, Bio-Rad Laboratories, Hercules, Calif.). To generate
cDNA, reverse transcription was performed using Superscript II reverse transcriptase (Invitrogen, Carlsbad, Calif.),
and 0.5 µg Oligo(dT) 12-18 primer at 42° C. for 20 minutes,
50° C. for 10 minutes and 42° C. for 1 hour in a gradient
thermocycler (Mastercycler gradient, Eppendorf, Westbury,
N.Y.). Primers for the pro-apoptotic protein Bax and the antiapoptotic protein Bcl-2 were designed using PrimerQuest
software (Integrated DNA Technologies, Coralville, Iowa)
and the NCBI gene bank sequences. Semi-quantitative PCR
was performed using RedTaq and a protocol consisting of 94 °
C. for 2 minutes, cycles of94° C. for 30 seconds, 69.5° C. for
30 sec and 72° C. for 1 minute, and a final extension at 72° C.
for 5 minutes. Band intensity was quantified using the ImageJ
software package (National Institutes of Health, Bethesda,
Md.) and normalized to the expression of three housekeeping
genes (Gapdh, ~-actin, cyclophillin).
ANOVA with Fisher's Protected Least Significant Difference (PLSD) post-hoc test was used to compare the ratio of
Bax to Bcl-2 for the three seasons (pre-hibernation, hibernation, post-hibernation). Though it did not achieve statistical
significance (p=0.300), the Bax/Bcl-2 ratio decreased by
approximately 42% during hibernation relative to pre-hibernation. The lack of statistical significance was likely related to
the small sample size (n=2 for each season). These data suggest that serum from hibernating bears contains a biological
molecule that decreases osteoblast apoptosis. Since endogenous PTH and the bone formation marker osteocalcin both
increase during hibernation (Donahue et al., 2006; J. Exp.
Biol., 209, 1630-8), it is possible that endogenous bear PTH
causes a decrease in osteoblast apoptosis during hibernation,
which in turn increases bone formation.

concentrations in 1 mM acetic acid, and diluted to 10 uM
working stock concentrations before use.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLOY4 cells (obtained from L. F. Bonewald, University of Missouri, Kansas City, Mo.) are maintained in alpha-minimum
essential media, 1% penicillin/streptomycin, and 10% serum
(MC-3T3: 10%fetal bovine serum(FBS), MLO-Y4: 5% FBS
and 5% bovine calf serum), at 37° C. in 5% CO 2 . All procedures described herein are repeated with independent cell
cultures such that n=6 for all treatment combinations in each
assay.
Effects of PTH Treatment on Intracellular cAMP Activity
MC-3 T3 and MLO-Y 4 cells are seeded at appropriate densities (MC-3T3: 50,000 cells/cm2 , MLO-Y4 15,000 cells/
cm2 ) in 6-well plates. Cells are cultured overnight to reach
optimal confluence. The culture media is then aspirated and
replaced with media containing either 10% serum+vehicle (1
mM acetic acid) or 10% serum+ 100 nM PTH (human or bear
1-84, or a sub fragment thereof. Cells are cultured under these
conditions for 10 or 30 minutes (Carter, P.H. et al., 1999, J.
Biol. Chem. 274 (45), 31955-60; Chen, X. eta!., 2002,Am. J.
Physiol. Cell Physiol. 283 (5), C1432-40; Schiller, P. C. et al.,
1999, J. Bone Miner. Res. 14 (9), 1504-12). Following culture, the cells are trypsinized, centrifuged, and resuspended in
lysis buffer. The suspension is incubated for 10 minutes and
centrifuged to separate cellular debris. The supernatant from
the cell lysate (following a 2-fold dilution) is assayed for
cAMP concentration using a competitive binding assay (Cyclic AMP Assay #KGE002, R&D Systems, Minneapolis,
Minn.).
With each of the polypeptides tested, there is an increase in
cellular cAMP levels in response to the black bear PTH-based
polypeptide.
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Example 6

40

Comparison of Effects of Black Bear vs. Human
PTH 1-84 or Subfragments Thereof on cAMP in
Bone Cell Lines
45

Full-length recombinant black bear PTH (residues 1-84) is
produced and its effects on levels of cyclic adenosine monophosphate (cAMP) concentration in bone cell lines (MC-3 T3
osteoblastic cells and MLO-Y4 osteocytic cells) are investigated and compared to results obtained using recombinant
human PTH 1-84. Equivalent experiments are conducted
using subfragments of black bear and human PTH, the subfragments including amino acid residues 1-34, 1-36, 7-84,
11-84, and41-52 of the full-length (1-84) mature protein. For
some experiments, black bear and human PTH polypeptides
are synthesized with solid-phase methods.
To determine the effect of various forms of recombinant
black bear and human PTH polypeptides on cAMP levels in
bone-forming cells, the cultured bone cells (MC-3T3 and
MLO-Y4) are contacted for 10 or 30 minutes with human or
black bear PTH full-length (i.e. amino acid residues 1-84)
polypeptide or one of the above-listed subfragments. After
the cell is contacted with the PTH polypeptide, cAMP concentration in the cell is measured using a competitive binding
assay as described further below.
For all of the experiments using recombinant polypeptides,
the lyophilized peptides are reconstituted to 100 uM stock

50

55

60

65

Comparison of Effects of Black Bear vs. Human
PTH 1-84 or Sub fragments Thereof on Apoptosis in
Bone Cell Lines
Full-length recombinant black bear PTH (residues 1-84) is
produced and its effects on apoptosis in bone cell lines (MC3 T3 osteoblastic cells and MLO-Y4 osteocytic cells) are
investigated and are compared to results obtained using
recombinant human PTH 1-84. Equivalent experiments are
conducted using sub fragments ofblack bear and human PTH,
the subfragments including amino acid residues 1-34, 1-36,
7-84, 11-84, and 41-52 of the full-length (1-84) mature protein. For some experiments, black bear and human PTH
polypeptides are synthesized with solid-phase methods.
To determine the relative ability of black bear and human
PTH to prevent osteoblast and osteocyte apoptosis (under
pro-apoptotic conditions), cells are incubated with human or
black bear PTH 1-84, or one of the subfragments listed above,
for one hour. Afterwards, cells are treated for 6 hours with
dexamethasone to induce apoptosis. Apoptosis is quantified
with an ELISA, as described further below.
For all of the experiments using recombinant polypeptides,
the lyophilized peptides are reconstituted to 100 uM stock
concentrations in 1 mM acetic acid, and diluted to 10 uM
working stock concentrations before use.
Additional experiments are performed with MC-3T3 cells
using either 0.1 % or 10% FBS. Additional experiments with
less (0.1 %) than the normal (10%) amountofFBS are run and
the results are analyzed to determine whether there is a significantly different response between experiments that are
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run with normal or lower levels of serum. In the experiments
reported in this Example, the results are not affected by the
amount of FBS that is used. Apoptosis protection studies
show that each of the polypeptides tested reduces or prevents
apoptosis in MC-3T3 cells.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLOY4 cells (obtained from L. F. Bonewald, University of Missouri, Kansas City, Mo.) are maintained in alpha-minimum
essential media, 1% penicillin/streptomycin, and 10% serum
(MC-3T3: 10%fetal bovine serum(FBS), MLO-Y4: 5%FBS
and 5% bovine calf serum), at 37° C. in 5% CO 2 . All procedures described herein are repeated with independent cell
cultures such that n=6 for all treatment combinations in each
assay.
Effects of PTH Treatment on Apoptosis
MC-3T3 cells are seeded at 50,000 cells/cm2 , and MLOY4 cells are seeded at 15,000 cells/cm2 in 6-well plates and
cultured overnight to reach optimal confluence. The culture
media is aspirated and replaced with media containing either
10% serum+vehicle (1 mM acetic acid) or 10% serum+l00
nM PTH (human or bear 1-84, or a subfragment thereof).
After a one-hour incubation (Jilka et al., 1999; J. Clin. Invest.,
104, 439-46), 10 µM dexamethasone or its vehicle (DMSO) is
added to each well and cells are incubated for 6 hours (Bellido, T. eta!., 2003, J. Biol. Chem. 278(50), 50259-72; Jilka et
al., 1999, J. Clin. Invest., 104, 439-46). The PTH polypeptide
or vehicle is left in situ during apoptosis induction because the
suppression of apoptosis by PTH is self-limiting (Bellido et
al., 2003). After 6 hours, cells are trypsinized, centrifuged,
resuspended, and counted using a hemocytometer. 50,000
cells are removed from the suspension and placed into lysis
buffer. The lysate supernatant (following centrifugation) is
removed for analysis and stored at -20° C.
Apoptosis is quantified from the lysate supernatant with an
ELISA (Cell Death Detection ELISA, #1544675, Roche
Applied Science, Indianapolis, Ind.). This assay detects
mono- and oligonucleosomes from fragmented cellular DNA
in the cytoplasmic fraction of cell lysates, and therefore provides a good measure of the early and middle stages of apoptosis. Briefly, samples are diluted in buffer solution and
added to microplate wells coated with an anti-histone mouse
monoclonal (clone Hl 1-4) antibody. Lysate supernatant from
the vehicle-treated cells serves as a negative control. Optical
densities are measured at 405 nm following the addition of a
peroxidase-conjugated anti-DNA mouse monoclonal (clone
MCA-33) antibody, and the amount of apoptosis in each
sample is determined relative to its corresponding negative
control. All samples are assayed in duplicate.
Each of the polypeptides tested decreased apoptosis of the
cells (under pro-apoptotic conditions).

(1-84) mature protein. For some experiments, black bear and
human PTH polypeptides are synthesized with solid-phase
methods.
To determine the effect of black bear and human PTH on
regulation of bone matrix, transcriptional regulatory, antiapoptosis (Bcl-2) genes, and the pro-apoptosis gene Bax,
cells are cultured for 1 or 3 hours with human or bear PTH
1-84 or a subfragment. Gene expression is quantified with
real-time PCR.
For all of the experiments using recombinant polypeptides,
the lyophilized peptides are reconstituted to 100 uM stock
concentrations in 1 mM acetic acid, and diluted to 10 uM
working stock concentrations before use.
Additional experiments are performed with MC-3T3 cells
using either 0.1 % or 10% FBS. Additional experiments with
less (0.1 %)than the normal (10%) amountofFBS are run and
the results are analyzed to determine whether there is a significantly different response between experiments that are
run with normal or lower levels of serum. In the experiments
reported in this Example, the results are not affected by the
amount ofFBS that is used. Real-time PCR is used to assess
gene expression levels at 1- and 3-hour time points following
addition of the polypeptide, showing in particular that black
bear PTH 1-34 upregulates gene expression in MC-3 T3 cells.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLOY4 cells (obtained from L. F. Bonewald, University of Missouri, Kansas City, Mo.) are maintained in alpha-minimum
essential media, 1% penicillin/streptomycin, and 10% serum
(MC-3T3: 10%fetal bovine serum(FBS), MLO-Y4: 5% FBS
and 5% bovine calf serum), at 37° C. in 5% CO 2 . All procedures described herein are repeated with independent cell
cultures such that n=6 for all treatment combinations in each
assay.
Effects of PTH Treatment on Gene Expression
MC-3T3 cells are seeded at a density of 50,000 cells/cm2 ,
andMLO-Y4 cells are seeded at a densityof15,000 cells/cm 2
in 6-well plates and cultured overnight to reach optimal confluence. The culture media are aspirated and replaced with
media containing either 10% serum+vehicle (1 mM acetic
acid) or 10% serum+l00 nM PTH (human or bear 1-84, or a
sub fragment as listed above). Cells are cultured under these
conditions for 1 or 3 hours; these time points correspond with
PTH-induced upregulation of c-fos and osteocalcin (Jiang et
al., 2004, J. Biol. Chem., 279, 5329-37; Chen et al., 2002).
Total RNA is isolated using the SV Total RNA Isolation
System (Promega, Madison, Wis.).
Reverse transcription to generate cDNA is performed
using Superscript II reverse transcriptase (Invitrogen, Carlsbad, Calif.), and 0.5 µg Oligo(dT) 12-18 primer at 42° C. for
20 minutes, 50° C. for 10 minutes and 42° C. for 1 hour in a
gradient thermocycler (Mastercycler gradient, Eppendorf,
Westbury, N.Y.). Primers for all genes ofinterest (osteocalcin,
osteopontin, type I collagen, c-fos, Runx2, Bax, Bcl-2,
SOST) and housekeeping genes (Gapdh, ~-actin, cyclophillin) are designed using PrimerQuest software (Integrated
DNA Technologies, Coralville, Iowa) and the NCBI gene
bank sequences, and the PCR conditions are optimized using
RNA from MC-3T3 and MLO-Y4 cells. Real-time PCR is
performed using the Mx3000P real-time PCR system (Stratagene, La Jolla, Calif.). The protocol involves a hot start at
95° C. for 10 minutes followed by 40 cycles of 95° C. for 30
seconds (denaturation), 69° C. for 1 minute (annealing) and
72° C. for 1 minute (extension). The exception to this protocol
is for c-fos, which has an annealing temperature of 66° C.
Each 25 µl reaction contains lx Absolute™ qPCR SYBR®
green mix (ABgene, Rochester, N.Y.), 0.1 µM forward and
reverse primer, and 2.5 ng total RNA equivalent cDNA template. Gene expression is determined using the relative standard curve method normalized to the geometric mean of the
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Example 7
55

Comparison of Effects of Black Bear vs. Human
PTH 1-84 or Subfragments Thereof on Gene
Expression in Bone Cell Lines
Full-length recombinant black bear PTH (residues 1-84) is
produced and its effects on levels of gene expression in bone
cell lines (MC-3T3 osteoblastic cells and MLO-Y4 osteocytic cells) are investigated and are compared to results
obtained using recombinant human PTH 1-84. Equivalent
experiments are conducted using subfragments of black bear
and human PTH, the subfragments including amino acid
residues 1-34, 1-36, 7-84, ll-84,and41-52ofthefull-length

60
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three housekeeping genes. All samples are measured in duplicate, and any samples with a coefficient of variation (CV)
greater than 10% are reanalyzed.
The polypeptides cause an upregulation of bone matrix,
transcriptional regulatory, and transcriptional activator genes,
and a decrease in the expression ratio ofBax/Bcl-2.

enous serum PTH concentrations are inversely related to apoptosis levels, in that higher serum PTH levels correspond to
lower rates of apoptosis, i.e. serum PTH concentrations are
negatively correlated with apoptosis levels.
5

Example 9

Example 8
Comparison of the Effects of Black Bear Serum
from Different Seasons on Bone Cell Apoptosis and
Gene Expression, and Correlation with Serum Levels
of PTH and Osteocalcin
Blood samples are collected from at least 3 different female
black bears (Ursus americanus pallas) held in the Virginia
Tech Center for Bear Research between 2004 and 2005.
Serum from additional black bears is collected in subsequent
years. The Virginia Polytechnic Institute and State University
Animal Care Committee approved all bear handling protocols (#98-069-F&WS). The bears are anesthetized with a 2: 1
mixture ofketamine (l00·mg/ml):xylazine (lO0·mg/ml); the
dosage is 1 cc of the mixture per45.5 kg of body mass. Blood
samples are drawn from the femoral vein while the bears are
anesthetized, and the samples are transported to the laboratory in an ice-packed cooler. Immediately on return to the
laboratory, the blood is centrifuged to isolate the serum,
which is then frozen at -20° C. Blood samples are collected
from each bear every 10 days from the beginning of October
until the end of May. Hibernation begins in early January and
ends in early April. Thus, the collection dates encompass an
active pre-hibernation period, a disuse hibernation period,
and an active post-hibernation remobilization period.
Aliquots of 10 µl of bear serum are assayed in duplicate for
osteocalcin concentration by radioimmunoassay (PattersonAllen et al., 1982; Anal. Biochem., 120, 1-7). This assay has
previously been validated for bears (Donahue et al., 2006; J.
Exp. Biol., 209, 1630-8). The antibody is guinea-pig anti-rat
osteocalcin and tracer is 125 I-labeled rat osteocalcin. Aliquots
of 100 µl of bear serum are assayed in duplicate for PTH
concentration (Donahue et al., 2006; J. Exp. Biol., 209, 16308) with an ELISA (Porcine Intact PTH ELISA Kit, #60-3305,
Immutopics, Inc., San Clemente, Calif.). This assay binds the
39-84 region of PTH, and requires the 13-34 region of PTH to
calorimetrically report PTH concentration. Thus, it provides
a good measure of intact (1-84) PTH concentration as well as
C-terminal subfragments 7-84 and 11-84. This ELISA has
been shown to cross-react with bear PTH (Donahue et al.,
2006; J. Exp. Biol., 209, 1630-8), and has 100% cross-reactivity with human PTH. To validate this assay for black bears,
samples of culture media containing 10 nM recombinant
black bear or human PTH 1-84 are assayed in duplicate. The
known concentration of the PTH samples is compared to the
measured concentration determined from the assay's standard curve. Any potential difference in cross-reactivity determined from these samples is used as a correction for endogenous black bear PTH concentration in the black bear serum
samples.
The procedures described above for recombinant black
bear PTH apoptosis and gene expression cell culture experiments with cultured bone-type cells are repeated, substituting
the 100 nM recombinant PTH-containing media with culture
media containing 10% black bear serum (from pre-hibernation, hibernation, or post-hibernation periods). The serum
volumes are calculated following the PTH ELISA described
above.
Serum from the hibernation and post-hibernation seasons
causes a greater prevention of apoptosis compared to prehibernation serum, because PTH is higher during hibernation
and post-hibernation than in pre-hibernation serum. Endog-

In Vivo Testing of Bear PTH
10
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Black bear PTH, either full-length (1-84) or one of several
functional subfragments thereof (1-34; 1-36; 7-84; 11-84;
41-52), are tested in vivo for anabolic stimulation of bone
cells compared to an equivalent human PTH or sub fragment.
Each of the PTH polypeptides is synthesized and suspended
in a pharmaceutically-appropriate carrier for subcutaneous
injection. Full-length PTH or a functional fragment thereof,
from either black bear or human, is administered to mice at a
dose of 40 µg/kg body weight daily for 7 weeks. Black bear
PTH or a functional fragments thereof cause greater increases
in bone strength, mass, and mineral content than the equivalent human PTH polypeptide.
Example 10
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Use of Bear PTH as Prophylactic Agent to Reduce or
Prevent Bone Loss
Osteoporosis is induced in mice by hindlimb suspension (a
disuse model of osteoporosis) and by ovariectomy (a postmenopausal model of osteoporosis). After the hindlimb suspension begins or the ovariectomy is completed, the mouse is
given regular doses of black bear PTH or a functional fragment thereof. The mice treated with black bear PTH or functional fragments thereof show less bone loss than untreated
mice.
Example 11
Bear and Human PTH 1-34 Both Upregulate Gene
Expression ofOsteocalcin, but Only Bear PTH 1-34
Decreases the Expression Ratio ofBax/Bcl-2
MC-3T3 cells were incubated in vehicle or 100 nM synthetic bear or human PTH 1-34 for 3 or 6 hours (n=2 or 4).
Total RNA was isolated, and cDNA was generated with
reverse transcription. Primers for the bone matrix proteins
type I collagen and osteocalcin, the pro-apoptotic protein
Bax, the anti-apoptotic protein Bcl-2, and the housekeeping
genes Gapdh, ~-actin, and cyclophillin were designed using
PrimerQuest software (Integrated DNA Technologies, Coralville, Iowa). Real-time PCR was performed using the
Mx3000P real-time PCR system (Strata gene, LaJolla, Calif.).
All samples were measured in duplicate. Gene expression
was determined using the relative standard curve method
normalized to the geometric mean of the three housekeeping
genes (Gapdh, ~-actin, and cyclophillin). Apoptosis-related
genes were analyzed as the expression ratio of Bax/Bcl-2,
since a decrease in this ratio is associated with decreased
apoptosis in vitro.
Culture in human or bear PTH 1-34 for 6 hours did not
affect expression of type I collagen but substantially upregulated the expression of osteocalcin compared to the vehicle
control (FIG. 6). There were no significant differences
between human and bear PTH (p>0.09).
Culture in bear PTH 1-34 for 3 hours decreased the expression ratio ofBax/Bcl-2, suggesting decreased apoptosis, but
culture in human PTH 1-34 for 3 hours increased the ratio,
suggesting increased apoptosis (FIG. 7). The difference
between bear and human PTH was statistically significant
(p=0.047).
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>

13

SEQ ID NO 1
LENGTH, 255
TYPE, DNA
ORGANISM, Ursus americanus
FEATURE,
NAME/KEY, CDS
LOCATION, (1) .. (252)
OTHER INFORMATION, cDNA encoding mature PTH polypeptide

<400> SEQUENCE,

1

tct gtg age gag ata cag ttt atg cat aac ctg ggc aaa cat ctg age
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15

48

tee atg gag agg gtg gaa tgg ctg egg aag aag ctg cag gac gtg cac
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30

96

aac ttt gtt gee ctt gga get cca aca gcg cac aga gat ggt ggt tee
Asn Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser
35
40
45

144

cag agg CCC cag aaa aag gaa gac aat gtg ctg gtt gag aac cat caa
Gln Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln
50
55
60

192

aaa agt etc gga gaa gca gac aaa get gat gtg gat gta tta ace aaa
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80

240

tct aaa CCC caa tga
Ser Lys Pro Gln

255

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 84
TYPE, PRT
ORGANISM, Ursus americanus

<400> SEQUENCE,

2

Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser
35
40
45
Gln Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80
Ser Lys Pro Gln

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>

SEQ ID NO 3
LENGTH, 348
TYPE, DNA
ORGANISM, Ursus americanus
FEATURE,
NAME/KEY, CDS
LOCATION, (1) .. (345)
OTHER INFORMATION, cDNA encoding full-length PTH polypeptide

<400> SEQUENCE, 3

atg atg tct gcg aaa aac gtg gtt aaa gta atg att gtc atg ttt gca
Met Met Ser Ala Lys Asn Val Val Lys Val Met Ile Val Met Phe Ala
1
5
10
15

48
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24
-continued

att tgt ttt ctt gca aaa tcg gat ggg aaa cct gtt aag aag aga tct
Ile Cys Phe Leu Ala Lys Ser Asp Gly Lys Pro Val Lys Lys Arg Ser
20
25
30

96

gtg age gag ata cag ttt atg cat aac ctg ggc aaa cat ctg age tee
Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser
35
40
45

144

atg gag agg gtg gaa tgg ctg egg aag aag ctg cag gac gtg cac aac
Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn
50
55
60

192

ttt gtt gee ctt gga get cca aca gcg cac aga gat ggt ggt tee cag
Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser Gln
65
70
75
80

240

agg CCC cag aaa aag gaa gac aat gtg ctg gtt gag aac cat caa aaa
Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln Lys
85
90
95

288

agt etc gga gaa gca gac aaa get gat gtg gat gta tta ace aaa tct
Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ser
100
105
110

336

aaa CCC caa tga
Lys Pro Gln
115

348

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH, 115
TYPE, PRT
ORGANISM, Ursus americanus

<400> SEQUENCE,

4

Met Met Ser Ala Lys Asn Val Val Lys Val Met Ile Val Met Phe Ala
1
5
10
15
Ile Cys Phe Leu Ala Lys Ser Asp Gly Lys Pro Val Lys Lys Arg Ser
20
25
30
Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser
35
40
45
Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn
50
55
60
Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser Gln
65
70
75
80
Arg Pro Gln Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gln Lys
85
90
95
Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ser
100
105
110
Lys Pro Gln
115

<210>
<211>
<212>
<213>

SEQ ID NO 5
LENGTH, 84
TYPE, PRT
ORGANISM, Macaca fascicularis

<400> SEQUENCE,

5

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Ile Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
35
40
45
Gln Arg Pro Arg Lys Lys Glu Asp Asn Ile Leu Val Glu Ser His Glu
50
55
60
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26
-continued

Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gln

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 84
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 6
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
35
40
45
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gln

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>

SEQ ID NO 7
LENGTH, 84
TYPE, PRT
ORGANISM, Equus caballus
FEATURE,
NAME/KEY, misc_feature
LOCATION, (65) .. (65)
OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE, 7
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Val Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Ile Ala Leu Gly Ala Pro Ile Phe His Arg Asp Gly Gly Ser
35
40
45
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Ile Glu Ser His Gln
50
55
60
Xaa Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ser Lys
65
70
75
80
Thr Lys Ser Gln

<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH, 84
TYPE, PRT
ORGANISM: Canis lupus familiaris

<400> SEQUENCE, 8
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro Ile Ala His Arg Asp Gly Ser Ser
35
40
45
Gln Arg Pro Leu Lys Lys Glu Asp Asn Val Leu Val Glu Ser Tyr Gln
50
55
60
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28
-continued

Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gln

<210>
<211>
<212>
<213>

SEQ ID NO 9
LENGTH, 84
TYPE, PRT
ORGANISM, Felis catus

<400> SEQUENCE, 9
Ser Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Val Glu Arg Val Glu Trp Leu Arg Arg Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro Ile Ala His Arg Asp Gly Gly Ser
35
40
45
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Pro Ala Glu Asn His Gln
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile Lys
65
70
75
80
Ala Lys Ser Gln

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH, 84
TYPE, PRT
ORGANISM, Bos taurus

<400> SEQUENCE,

10

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Ser Ile Ala Tyr Arg Asp Gly Ser Ser
35
40
45
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gln
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ile Lys
65
70
75
80
Ala Lys Pro Gln

<210>
<211>
<212>
<213>

SEQ ID NO 11
LENGTH, 84
TYPE, PRT
ORGANISM, Sus scrofa

<400> SEQUENCE, 11
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Ser Ile Val His Arg Asp Gly Gly Ser
35
40
45
Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gln
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Ala Val Asp Val Leu Ile Lys
65
70
75
80
Ala Lys Pro Gln
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<210> SEQ ID NO 12
<211> LENGTH, 84
<212> TYPE, PRT
<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE, 12
Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala
1
5
10
15
Ser Val Glu Arg Met Gln Trp Leu Arg Lys Lys Leu Gln Asp Val His
20
25
30
Asn Phe Val Ser Leu Gly Val Gln Met Ala Ala Arg Glu Gly Ser Tyr
35
40
45
Gln Arg Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Ser
50
55
60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65
70
75
80
Ala Lys Ser Gln

<210>
<211>
<212>
<213>

SEQ ID NO 13
LENGTH, 84
TYPE, PRT
ORGANISM, Mus musculus

<400> SEQUENCE, 13
Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala
1
5
10
15
Ser Met Glu Arg Met Gln Trp Leu Arg Arg Lys Leu Gln Asp Met His
20
25
30
Asn Phe Val Ser Leu Gly Val Gln Met Ala Ala Arg Asp Gly Ser His
35
40
45
Gln Lys Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Pro
50
55
60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65
70
75
80
Ser Lys Ser Gln

What is claimed is:
1. A method of increasing cAMP levels in a bone-forming
cell comprising contacting the bone-forming cell with an
effective amount of a polypeptide comprising amino acid
residues 1-34 of SEQ ID NO: 2, wherein contacting the
bone-forming cell with the polypeptide increases cAMP levels in the bone-forming cell, and wherein the bone-forming
cell is in a human subject.
2. The method of claim 1, wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO:2.
3. The method of claim 1, wherein the polypeptide comprises SEQ ID NO: 2.
4. A method ofreducing apoptosis in a bone-forming cell
comprising contacting the bone-forming cell with an effective amount of a polypeptide comprising amino acid residues
1-34 of SEQ ID NO: 2, wherein contacting the bone-forming
cell with the polypeptide reduces apoptosis in the bone-forming cell, and wherein the bone-forming cell is in a human
subject.
5. The method of claim 4, wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.
6. The method of claim 4, wherein the polypeptide comprises SEQ ID NO: 2.
7. A method of decreasing the ratio of expression levels of
Bax protein to Bcl-2 protein in a bone-forming cell compris-

45

50

55

60

65

ing contacting the bone-forming cell with an effective amount
of a polypeptide comprising amino acid residues 1-34 of SEQ
ID NO: 2, wherein contacting the bone-forming cell with the
polypeptide decreases the ratio of expression levels of Bax
protein to Bcl-2 protein in the bone-forming cell, and wherein
the bone-forming cell is in a human subject.
8. The method of claim 7, wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.
9. The method of claim 7, wherein the polypeptide comprises SEQ ID NO: 2.
10. A method of increasing the expression level of one or
more of a bone matrix protein, a transcriptional activator, or a
transcriptional regulator in a bone-forming cell comprising
contacting the bone-forming cell with an effective amount of
a polypeptide comprising amino acid residues 1-34 of SEQ
ID NO: 2, wherein contacting the bone-forming cell with the
polypeptide increases the expression level of the bone matrix
protein, the transcriptional activator, or the transcriptional
regulator in the bone-forming cell, and wherein the boneforming cell is in a human subject.
11. The method of claim 10, wherein polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.
12. The method of claim 10, wherein the polypeptide comprises SEQ ID NO: 2.
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13. A method of enhancing bone mineral density, increas-

16. The method of claim 13, wherein the polypeptide com-

ing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a
human subject, comprising contacting a bone-forming cell in
the human subject with an effective amount of a polypeptide
comprising amino acid residues 1-34 of SEQ ID NO: 2,
wherein contacting the bone-forming cell with the polypeptide enhances bone mineral density, increases bone mass,
decreases bone loss, or reduces the incidence of bone fractures in the human subject.

prises amino acid residues 1-36 of SEQ ID NO: 2.
17. The method of claim 13, wherein the polypeptide comprises SEQ ID NO: 2.
18. A method of enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a
human subject, comprising contacting a bone-forming cell in
the human subject with an effective amount of a polypeptide
comprising bear parathyroid hormone or a functional fragment thereof, wherein contacting the bone-forming cell with
the polypeptide enhances bone mineral density, increases
bone mass, decreases bone loss, or reduces the incidence of
bone fractures in the human subject.

14. The method of claim 13, wherein the human subject is
a post-menopausal female human afflicted with osteoporosis.
15. The method of claim 13 further comprising administering vitamin D and calcium to the human subject.
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It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the specification:

Col. 7, line 13, "down-regulates" should read --downregulates--.
Col. 11, line 59, "4"' should read --4°--.
Col. 16, line 20, insert --)-- after "thereof'.
Col. 19, line 43, "calorimetrically" should read --colorimetrically--.

In the claims:
Col. 30, line 64, Claim 11 - insert --the-- after "wherein".
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